Home page4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Chiusura precedente
2238,00 ¥
Intervallo giornaliero
2254,00 ¥ - 2292,00 ¥
Intervallo annuale
1921,00 ¥ - 2411,00 ¥
Cap di mercato
120,62 Mld JPY
Volume medio
63.597,00
Rapporto P/E
12,03
Dividendo/Prezzo
1,96%
Borsa valori principale
TYO
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
(JPY) | set 2024info | Variazione Y/Y |
---|---|---|
Entrate | 20,97 Mld | 14,11% |
Spese di gestione | 12,52 Mld | 14,20% |
Utile netto | 1,85 Mld | -25,47% |
Margine di profitto netto | 8,82 | -34,67% |
Utili per azione | — | — |
EBITDA | 4,39 Mld | 8,29% |
Aliquota fiscale effettiva | 17,59% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(JPY) | set 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 24,36 Mld | 31,90% |
Totale attivo | 158,34 Mld | 6,87% |
Totale passivo | 69,77 Mld | -3,36% |
Patrimonio netto totale | 88,57 Mld | — |
Azioni in circolazione | 44,08 Mln | — |
Prezzo/valore contabile | 1,12 | — |
Redditività dell'attivo | 4,06% | — |
Rendimento sul capitale | 4,89% | — |
Flusso di cassa
Flusso di cassa netto
(JPY) | set 2024info | Variazione Y/Y |
---|---|---|
Utile netto | 1,85 Mld | -25,47% |
Liquidità di esercizio | — | — |
Contanti da investimenti | — | — |
Contanti da finanziamenti | — | — |
Flusso di cassa netto | — | — |
Flusso di cassa libero | — | — |
Informazioni
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
CEO
Fondazione
22 dic 1955
Sito web
Dipendenti
1.777